Theratechnologies Inc.

Theratechnologies Inc. is a biotechnology company focused on developing innovative therapies to address unmet medical needs, particularly in HIV and oncology, aiming to improve patient outcomes through specialized treatments. Founded in 1993 and headquartered in Montreal, Canada, Theratechnologies Inc. develops and commercializes therapies for HIV and oncology.

The company has undergone strategic pivots to enhance its product pipeline, including the introduction of Trogarzo® and EGRIFTA SV®. CEO Paul Levesque leads the firm, which has participated in 3 investment deals, the most recent occurring on December 2, 2024. Theratechnologies specializes in innovative therapies primarily addressing unmet medical needs in HIV and oncology. It markets Trogarzo®, a monoclonal antibody for patients with limited treatment options, and EGRIFTA SV®, aimed at managing lipodystrophy in HIV patients.

The company's pipeline includes the F8 formulation of tesamorelin, which offers improved dosing through a multi-dose vial system, catering to healthcare providers and patients in the United States. Theratechnologies generates revenue through the sales of its prescription products Trogarzo® and EGRIFTA SV® to healthcare providers, pharmacies, and hospitals in the United States. The pricing structure reflects their specialized formulations, leading to revenue from both one-time purchases and recurring orders, as patients continue their treatment regimens in HIV and oncology. In December 2024, Theratechnologies secured a USD 15 mn second-ranking secured subordinated term loan and USD 40 mn in senior secured financing from Investissement Québec and TD Bank.

This financing will refinance existing debt and provides a USD 20 mn accordion feature, potentially increasing total commitments to USD 60 mn. The company is likely to use these funds to support the development of new products and expand its market presence in regions prioritizing innovative healthcare solutions.